Houston, TX (April 2, 2007) CytoGenix, Inc. (CYGX.OB) announced today that Richard Willson, Ph.D. has agreed to join the Company's Scientific Advisory Board. Dr. Wilson is a Professor in the Department of Chemical & Biomolecular Engineering at the University of Houston. Professor Willson brings to the SAB a vast knowledge base in the area of biomolecular recognition as it applies to separation technology and molecular diagnostics. More information on his work and accomplishments may be found at www.chee.uh.edu/faculty/willson.
Malcolm Skolnick, Chairman and CEO of CytoGenix stated "Dr. Willson is capable of making an immediate, substantive contribution to the Company's goal of commercialization of synDNA™. Dr. Willson's expertise in DNA purification strategies and nanostructured adsorbents will assist CytoGenix in addressing key issues in the scale-up technology necessary for commercial-scale synDNA™ production. We are delighted to have Dr. Willson join our SAB."
Dr. Willson stated, "I am excited to be working with CytoGenix to bring synDNA™ into the realm of commercial scale manufacturing. This novel drug substance represents an opportunity to develop many new products with distinct advantages over existing plasmid-based technology."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNATM production and ssDNA expression technologies. The company has developed a breakthrough cell-free process for large-scale production of high purity DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside a cell. CytoGenix currently holds 11 granted patents and about 36 international or US pending patent applications claiming methods and materials in connection with these platform technologies.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: Malcolm Skolnick (713) 789-0070.
